Table 2 Anamnestic data of 1009 patients with “Triple Negative” breast cancer based on histologic subtypes. Sardinia, Italy 1994–2015
IBC-NST (n = 744) n (%) | Lobular (n = 62) n (%) | Apocrine (n = 43) n (%) | Adenoid cystic (n = 6) n (%) | Metaplastic (n = 46) n (%) | Medullary (n = 39) n (%) | Other (n = 27) n (%) | p value* | |
|---|---|---|---|---|---|---|---|---|
Age | ||||||||
< 35 | 34 (4.6) | 0 (0.0) | 2 (4.7) | 1 (16.7) | 3 (6.5) | 6 (15.4) | 1 (3.7) | < 0.001 |
35–49 | 214 (28.8) | 10 (16.1) | 1 (2.3) | 1 (16.7) | 8 (17.4) | 12 (30.8) | 8 (29.6) | |
50–69 | 354 (47.6) | 36 (58.1) | 22 (51.2) | 3 (50.0) | 26 (56.5) | 18 (46.2) | 16 (59.3) | |
70+ | 141 (19.0) | 16 (25.8) | 18 (41.9) | 1 (16.7) | 9 (19.6) | 3 (7.7) | 2 (7.4) | |
Missing | 1 | |||||||
Age at menarche | ||||||||
< 13 | 208 (45.9) | 10 (31.3) | 11 (37.9) | 0 (0.0) | 9 (27.3) | 7 (43.8) | 4 (19.0) | 0.036 |
≥ 13 | 245 (54.1) | 22 (68.8) | 18 (62.1) | 2 (100.0) | 24 (72.7) | 9 (56.3) | 17 (81.0) | |
Missing | 291 | 30 | 14 | 4 | ||||
Age at menopause | ||||||||
< 45 | 34 (11.8) | 3 (12.0) | 2 (7.7) | 1 (50.0) | 1 (4.3) | 2 (18.2) | 1 (7.7) | 0.519 |
≥ 45 | 253 (88.2) | 22 (88.0) | 24 (92.3) | 1 (50.0) | 22 (95.7) | 9 (81.8) | 12 (92.3) | |
Missing | 457 | 37 | 17 | 3 | 23 | 27 | 14 | |
Menopausal status | ||||||||
yes | 210 (47.6) | 18 (66.7) | 17 (63.0) | 1 (33.3) | 20 (60.6) | 10 (52.6) | 12 (54.5) | 0.124 |
post surgical | 39 (8.8) | 3 (11.1) | 4 (14.8) | 1 (33.3) | 2 (6.1) | 2 (10.5) | 1 (4.5) | |
post treatment | 2 (0.5) | 0 (0.0) | 1 (3.7) | 0 (0.0) | 0 (0.0) | 1 (5.3) | 0 (0.0) | |
no | 190 (43.1) | 6 (22.2) | 5 (18.5) | 1 (33.3) | 11 (33.3) | 6 (31.6) | 9 (40.9) | |
Missing | 303 | 35 | 16 | 3 | 13 | 20 | 5 | |
Nulliparity | ||||||||
yes | 80 (16.4) | 1 (3.1) | 7 (25.0) | 0 (0.0) | 7 (19.4) | 4 (25.0) | 4 (20.0) | 0.280 |
no | 409 (83.6) | 31 (96.9) | 21 (75.0) | 3 (100.0) | 29 (80.6) | 12 (75.0) | 16 (80.0) | |
Missing | 255 | 30 | 15 | 3 | 10 | 22 | 7 | |
Family history of breast cancer | ||||||||
yes | 166 (33.8) | 9 (23.7) | 11 (36.7) | 3 (100.0) | 13 (37.1) | 9 (45.0) | 5 (21.7) | 0.104 |
no | 325 (66.2) | 29 (76.3) | 19 (63.3) | 0 (0.0) | 22 (62.9) | 11 (55.0) | 18 (78.3) | |
Missing | 253 | 24 | 13 | 3 | 11 | 19 | 4 | |
Family history of other than breast cancer | ||||||||
yes | 137 (29.1) | 14 (38.9) | 6 (20.7) | 0 (0.0) | 8 (25.0) | 6 (35.3) | 10 (45.5) | 0.309 |
no | 333 (70.9) | 22 (61.1) | 23 (79.3) | 3 (100.0) | 24 (75.0) | 11 (64.7) | 12 (54.5) | |
Missing | 274 | 26 | 14 | 3 | 14 | 20 | 5 | |
Other concomitant primary cancer | ||||||||
yes | 11 (4.5) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.870 |
no | 231 (95.5) | 19 (95.0) | 12 (100.0) | 2 (100.0) | 19 (100.0) | 8 (100.0) | 11 (100.0) | |
Missing | 502 | 42 | 31 | 4 | 27 | 31 | 16 | |
Other previous primary cancer | ||||||||
yes | 19 (7.3) | 1 (5.0) | 3 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0.361 |
no | 242 (92.7) | 19 (95.0) | 12 (80.0) | 2 (100.0) | 19 (100.0) | 8 (88.9) | 11 (100.0) | |
Missing | 483 | 42 | 28 | 4 | 27 | 30 | 16 | |
BMI | ||||||||
< 18 underweight | 14 (3.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 0.183 |
18–24.9 normal range | 235 (50.8) | 15 (46.9) | 11 (42.3) | 1 (33.3) | 18 (54.5) | 8 (47.1) | 8 (40.0) | |
25–30 overweight | 135 (29.2) | 11 (34.4) | 7 (26.9) | 1 (33.3) | 11 (33.3) | 7 (41.2) | 7 (35.0) | |
> 30 0bese | 79 (17.1) | 6 (18.8) | 8 (30.8) | 0 (0.0) | 4 (12.1) | 2 (11.8) | 3 (15.0) | |
Missing | 281 | 30 | 17 | 3 | 13 | 22 | 7 | |
Drinking | ||||||||
yes | 21 (4.9) | 1 (3.1) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 3 (21.4) | 1 (4.8) | 0.015 |
no | 407 (95.1) | 31 (96.9) | 22 (100.0) | 2 (66.7) | 32 (100.0) | 11 (78.6) | 20 (95.2) | |
Missing | 316 | 30 | 21 | 3 | 14 | 24 | 6 | |
Smoking | ||||||||
yes | 92 (20.2) | 5 (14.7) | 4 (16.0) | 1 (3.3) | 7 (21.2) | 3 (18.8) | 3 (13.6) | 0.942 |
no | 364 (79.8) | 29 (85.3) | 21 (84.0) | 2 (66.7) | 26 (78.8) | 13 (81.3) | 19 (86.4) | |
Missing | 288 | 28 | 18 | 3 | 13 | 22 | 5 | |